CTMX
CytomX Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$647.67M
P/E Ratio
—
EPS
$-0.52
Beta
2.09
52W High
$8.21
52W Low
$1.72
50-Day MA
$3.96
200-Day MA
$4.03
Dividend Yield
—
Profit Margin
-166.40%
Forward P/E
7.43
PEG Ratio
-1.80
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $35.54M |
| Gross Profit (TTM) | $35.54M |
| EBITDA | $-60.62M |
| Operating Margin | -191.80% |
| Return on Equity | -34.30% |
| Return on Assets | -16.90% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $1.47 |
| Price-to-Book | 2.02 |
| Price-to-Sales (TTM) | 18.22 |
| EV/Revenue | 8.52 |
| EV/EBITDA | 24.67 |
| Quarterly Earnings Growth (YoY) | 60.60% |
| Quarterly Revenue Growth (YoY) | -79.90% |
| Shares Outstanding | $217.70M |
| Float | $186.26M |
| % Insiders | 0.56% |
| % Institutions | 96.33% |
Historical Volatility
HV 10-Day
58.07%
HV 20-Day
52.58%
HV 30-Day
44.73%
HV 60-Day
52.37%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($12.44 target)
3
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026